研究报告 |
|
|
|
|
细菌性腹泻三联口服疫苗的研制及其免疫效果的初步评价 |
刘地1, 晏婷1, 何秀娟2, 郑文云2, 马兴元1 |
1. 华东理工大学生物工程学院 生物反应器工程国家重点实验室 上海 200237; 2. 华东理工大学药学院 上海市新药设计重点实验室 上海 200237 |
|
Preparation and Preliminary Evaluation of Triple Oral Vaccine Against Bacterial Diarrhea |
LIU Di1, YAN Ting1, HE Xiu-juan2, ZHENG Wen-yun2, MA Xing-yuan1 |
1. School of Biotechnology and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China; 2. School of Pharmacy, Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai 200237, China |
引用本文:
刘地, 晏婷, 何秀娟, 郑文云, 马兴元. 细菌性腹泻三联口服疫苗的研制及其免疫效果的初步评价[J]. 中国生物工程杂志, 2017, 37(7): 18-26.
LIU Di, YAN Ting, HE Xiu-juan, ZHENG Wen-yun, MA Xing-yuan. Preparation and Preliminary Evaluation of Triple Oral Vaccine Against Bacterial Diarrhea. China Biotechnology, 2017, 37(7): 18-26.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20170706
或
https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I7/18
|
[1] Sanchez J,Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Current Opinion in Immunology, 2005, 17(4): 388-398. [2] Liu L, Johnson H L, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet, 2012, 379(9832): 2151-2161. [3] Zaidi D,Wine E. An update on travelers’ diarrhea. Curr Opin Gastroenterol, 2015, 31(1): 7-13. [4] Das J K, Tripathi A, Ali A, et al. Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health, 2013, 13(Suppl 3): S11. [5] Wenneras C,Erling V. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J Health Popul Nutr, 2004, 22(4): 370-382. [6] Svennerholm A M,Steele D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol, 2004, 18(2): 421-445. [7] Peirano G, Souza F S,Rodrigues D P. Frequency of serovars and antimicrobial resistance in Shigella spp. from Brazil. Memorias do Instituto Oswaldo Cruz, 2006, 101(3): 245-250. [8] Das J K, Ali A, Salam R A, et al. Antibiotics for the treatment of Cholera, Shigella and Cryptosporidium in children. BMC Public Health, 2013, 13(Suppl 3): S10. [9] Ogra P L, Faden H,Welliver R C. Vaccination strategies for mucosal immune responses. Clinical Microbiology Reviews, 2001, 14(2): 430-445. [10] Hoebe K, Janssen E,Beutler B. The interface between innate and adaptive immunity. Nature Immunology, 2004, 5(10): 971-974. [11] da Hora V P, Conceicao F R, Dellagostin O A, et al. Non-toxic derivatives of LT as potent adjuvants. Vaccine, 2011, 29(8): 1538-1544. [12] Rappuoli R, Pizza M, Douce G, et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunology Today, 1999, 20(11): 493-500. [13] Melton-Celsa A R. Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr, 2014, 2(4): Ehec-0024-2013. [14] Klose K E,Mekalanos J J. Differential regulation of multiple flagellins in Vibrio cholerae. Journal of Bacteriology, 1998, 180(2): 303-316. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|